UTHR Investors - Our Quick Report For You.

By Susan Ramirez • Thursday, April 06 15:04 • Permanent Link

Large-cap Health Care company United Therapeutics has moved -2.3% so far today on a volume of 605,904, compared to its average of 553,750. In contrast, the S&P 500 index moved 0.0%.

United Therapeutics trades -21.0% away from its average analyst target price of $288.0 per share. The 11 analysts following the stock have set target prices ranging from $150.0 to $375.0, and on average have given United Therapeutics a rating of buy.

Anyone interested in buying UTHR should be aware of the facts below:

United Therapeutics's current price is 59.5% above its Graham number of $142.66, which implies that at its current valuation it does not offer a margin of safety
United Therapeutics has moved 22.6% over the last year, and the S&P 500 logged a change of -9.1%
Based on its trailing earnings per share of 15.52, United Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 14.7 while the S&P 500 average is 15.97
UTHR has a forward P/E ratio of 10.9 based on its forward 12 month price to earnings (EPS) of $20.93 per share
The company has a price to earnings growth (PEG) ratio of 0.68 — a number near or below 1 signifying that United Therapeutics is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.2 compared to its sector average of 4.16
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Based in Silver Spring, the company has 985 full time employees and a market cap of $10,535,025,664.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.